Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Board Changes

26 Apr 2016 07:00

RNS Number : 2839W
Premier Veterinary Group PLC
26 April 2016
Β 

Β 

Β 

Β 

Β 

Β 

PREMIER VETERINARY GROUP PLC

("PVG" or "the Company")

Β 

Β 

BOARD CHANGES

Β 

London, UK, 26 April 2016 - Premier Veterinary Group plc (LSE: PVG) announces that Juliet Thompson has been appointed as a director and as the independent non-executive Chairman of the Company with effect from 25 April 2016. She succeeds as Chairman Iain Ross who oversaw the successful reverse takeover of the Company into Ark Therapeutics early last year. Iain Ross will remain on the Board as a non-executive director.

Daniel Smith, the Chief Financial Officer, will be leaving the Company in September this year to move to another part of the UK. The Board has commenced a comprehensive recruitment process to identify Daniel's replacement and a further announcement will be made in due course.

Juliet Thompson, a chartered accountant, is currently also a non-executive director of Nexstim, a medical technology company quoted on Nasdaq in Finland and Sweden and was Vice President of Corporate Finance of Precision Ocular, a company focused on retinal diseases, for which she recently led a successful fundraising. Juliet has built a strong track record advising healthcare corporates on strategy and the capital markets. She formerly headed up the healthcare team at Stifel and was a founder of Code Securities, a healthcare investment banking boutique, which became Nomura Code Securities where she was Head of Corporate Finance.

There are no further disclosures required under LR 9.6.13.

Iain Ross, non-executive and former Chairman commented:

"As previously indicated, we have been looking to strengthen our Board with the appointment of an additional independent director. Having been able to attract someone of Juliet's calibre, the Board feels it is appropriate that she joins as our independent non-executive Chairman. She brings extensive City and corporate experience which will be invaluable as we seek to grow the business aggressively."

Β For further information, please contact:

Β 

Premier Veterinary Group plc Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive Officer

Daniel Smith, Chief Financial Officer

Β 

Square1 Consulting Tel: +44 (0)207 929 5599

David Bick/Brian Alexander

Β 

Β 

Β 

Note to Editors:

Β 

PVG's services to third party veterinary practices, through its wholly-owned subsidiary Premier Vet Alliance ("PVA"), include the administration and support of a preventative healthcare program for pets branded "Pet Care Plan"; and the operation of a buying group (the "PVA Buying Group") which offers enhanced discounts to member practices on pharmaceutical and consumable spending.

Β 

Pet Care Plan is a structured, preventative healthcare program for cats, dogs and rabbits and is available only through veterinary practices. The program is seen as a way of providing gold standard care for pets at an affordable price for the client, by way of fixed monthly payments.

Β 

Pet Care Plan uses a clinical approach to prevention, as this is the most effective method of ensuring illnesses are diagnosed more quickly and not given a chance to advance. What truly sets Pet Care Plan apart is its unique approach of offering an end-to-end solution and support to the practice, which has been proven to work extremely well. PVA works alongside practices to create a tailor-made, cost-effective service for clients, one that delivers excellent care to their patients and significantly improves practice performance.

Β 

The PVA Buying Group, is now the UK's largest veterinary buying group without group interests in veterinary practices or veterinary wholesalers, offering its members the best discounts across the industry on pharmaceutical and consumable spend.

Β 

For further details: http://www.premiervetalliance.co.uk/

Β 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BOAUVOWRNWASUAR
Date   Source Headline
19th May 20087:00 amRNSResearch Update
16th May 20087:00 amRNSInterim Management Statement
24th Apr 20084:57 pmRNSAGM Results
22nd Apr 20087:00 amRNSRegulatory Update
17th Apr 20087:00 amRNSProduct Update
1st Apr 20083:26 pmRNSAnnual Information Update
31st Mar 200812:39 pmRNSTotal Voting Rights
28th Mar 20081:46 pmRNSRe Appointment
20th Mar 20087:00 amRNSBoard Appointment
11th Mar 20087:01 amRNSLaunch of Neuropad
11th Mar 20087:01 amRNSFinal Results
5th Mar 20085:20 pmRNSHolding(s) in Company
13th Feb 20087:00 amRNSManufacturing Update
31st Jan 200810:27 amRNSVoting Rights and Capital
23rd Jan 20084:56 pmRNSNotice of Results
18th Jan 20087:01 amRNSResearch Update
17th Jan 200810:42 amRNSRe: Employee Benefit Trust
11th Jan 200810:33 amRNSDirector/PDMR Shareholding
9th Jan 20084:50 pmRNSResignation of NED
8th Jan 20087:00 amRNSAcquisition
19th Dec 20074:37 pmRNSPrice Monitoring Extension
6th Dec 20075:48 pmRNSHolding(s) in Company
5th Dec 20071:39 pmRNSHolding(s) in Company
5th Dec 200712:41 pmRNSHolding(s) in Company
4th Dec 20075:40 pmRNSBlocklisting Interim Review
4th Dec 20074:56 pmRNSBlocklisting Interim Review
4th Dec 200711:50 amRNSHolding(s) in Company
30th Nov 200712:35 pmRNSDirector/PDMR Shareholding
30th Nov 200712:10 pmRNSVoting Rights and Capital
29th Nov 20072:17 pmRNSResult of EGM
28th Nov 20074:27 pmRNSRe: Placing and Open Offer
6th Nov 20077:01 amRNSPlacing and Open Offer
30th Oct 20075:08 pmRNSHolding(s) in Company
25th Oct 20077:01 amRNSResearch Update
22nd Oct 20071:01 pmRNSHolding(s) in Company
16th Oct 20073:23 pmRNSHolding(s) in Company
10th Oct 20077:01 amRNSRe Agreement
8th Oct 20077:00 amRNSRe Agreement
28th Sep 20073:06 pmRNSVoting Rights and Capital
31st Aug 200710:39 amRNSVoting Rights and Capital
29th Aug 20077:01 amRNSInterim Results
20th Aug 20077:02 amRNSRe: Product Launch
31st Jul 200711:23 amRNSVoting Rights and Capital
26th Jul 20077:01 amRNSResearch Update
24th Jul 200711:18 amRNSNotice of Results
23rd Jul 20077:01 amRNSRe: Cerepro
6th Jul 20077:00 amRNSEPO Grant Stroke Patent
29th Jun 20071:14 pmRNSVoting Rights and Capital
22nd Jun 20074:03 pmRNSHolding(s) in Company
15th Jun 20072:45 pmRNSDirector's Share Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.